Artal Group S.A. Chemo Centryx, Inc. Transaction History

Artal Group S.A.

$214 Million
Q3 2024

Shares

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Aug 13, 2021	SELL	$9.59 - $50.88 $7.19 Million - $38.2 Million	-750,000 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$49.53 - $68.4 $4.95 Million - $6.84 Million	100,000 Added 15.38%	750,000 $38.4 Million
Q4 2020 Feb 11, 2021	BUY	$47.25 - $65.16 $30.7 Million - $42.4 Million	650,000 New	650,000 $40.2 Million
Q1 2018 May 10, 2018	SELL	$5.9 - $14.99 $2.95 Million - $7.5 Million	-500,000 Closed	0 $0
Q3 2017 Nov 08, 2017	BUY	$6.5 - $10.69 $3.25 Million - $5.35 Million	500,000	500,000 $3.71 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.